Pfizer Inc. (NYSE:PFE) – Investment analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for Pfizer in a report released on Thursday. Jefferies Group analyst J. Holford anticipates that the firm will earn $0.63 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $36.00 target price on the stock.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.56 EPS.

Earnings History and Estimates for Pfizer (NYSE:PFE)

Several other brokerages have also recently weighed in on PFE. Sanford C. Bernstein set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Barclays PLC reaffirmed an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a report on Tuesday, August 2nd. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.97 target price on the stock. in a report on Thursday, July 14th. Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Eleven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $38.59.

Pfizer (NYSE:PFE) traded down 0.09% during mid-day trading on Friday, hitting $32.73. 5,492,023 shares of the stock traded hands. The stock has a market cap of $198.53 billion, a PE ratio of 29.02 and a beta of 0.86. The company has a 50 day moving average of $34.08 and a 200-day moving average of $34.25. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Pfizer by 1.6% in the second quarter. Vanguard Group Inc. now owns 383,339,513 shares of the biopharmaceutical company’s stock valued at $13,497,386,000 after buying an additional 6,193,821 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Pfizer by 3.2% in the second quarter. BlackRock Fund Advisors now owns 95,416,739 shares of the biopharmaceutical company’s stock valued at $3,359,623,000 after buying an additional 2,927,618 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after buying an additional 3,936,078 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. Finally, BlackRock Group LTD increased its position in shares of Pfizer by 0.9% in the second quarter. BlackRock Group LTD now owns 60,027,464 shares of the biopharmaceutical company’s stock valued at $2,113,568,000 after buying an additional 552,493 shares during the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.66%. Pfizer’s dividend payout ratio is presently 95.24%.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.